WO2001024832A3 - Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung - Google Patents

Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung Download PDF

Info

Publication number
WO2001024832A3
WO2001024832A3 PCT/DE2000/003443 DE0003443W WO0124832A3 WO 2001024832 A3 WO2001024832 A3 WO 2001024832A3 DE 0003443 W DE0003443 W DE 0003443W WO 0124832 A3 WO0124832 A3 WO 0124832A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
cea
express
treating
mucin
Prior art date
Application number
PCT/DE2000/003443
Other languages
English (en)
French (fr)
Other versions
WO2001024832A2 (de
Inventor
Gabriele Pecher
Original Assignee
Gabriele Pecher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gabriele Pecher filed Critical Gabriele Pecher
Priority to AU19919/01A priority Critical patent/AU1991901A/en
Priority to EP00982945A priority patent/EP1409534A2/de
Publication of WO2001024832A2 publication Critical patent/WO2001024832A2/de
Publication of WO2001024832A3 publication Critical patent/WO2001024832A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es wird eine pharmazeutische Zusammensetung beteithestellt, die ein Plasmid ('nackte DAN') aufweist, das als therapeutisches Gen das humane Muzingen MUC1, wirksame Fragmente davon oder mindestens 3 Repeats der Aminosäuresequenz SEQ No. 1 enthält und/oder ein anderes Plasmid ('nackte DNA'), das als thereapeutisches Gen das Gen für das humane Carcinoembryonale Antigen (CEA)SEQ No. 2 enthält. Die pharmazeutische Zusammensetzung wird vorzugsweise als Impfstoff bereit-gestellt und es werden in Abhängigkeit vom jeweiligen Tumor die Plasmide mit dem jeweiligen therapeutischen Gen entweder einzeln oder gemeinsam appliziert.
PCT/DE2000/003443 1999-09-27 2000-09-26 Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung WO2001024832A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU19919/01A AU1991901A (en) 1999-09-27 2000-09-26 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
EP00982945A EP1409534A2 (de) 1999-09-27 2000-09-26 Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19948105.9 1999-09-27
DE19948105 1999-09-27

Publications (2)

Publication Number Publication Date
WO2001024832A2 WO2001024832A2 (de) 2001-04-12
WO2001024832A3 true WO2001024832A3 (de) 2002-04-18

Family

ID=7924664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/003443 WO2001024832A2 (de) 1999-09-27 2000-09-26 Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung

Country Status (4)

Country Link
EP (1) EP1409534A2 (de)
AU (1) AU1991901A (de)
DE (1) DE10048710A1 (de)
WO (1) WO2001024832A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
CA2545164C (en) 2003-11-12 2016-11-29 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Recombinant vectors expressing mucin and carcinoembryoinic antigen
JP5285855B2 (ja) * 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
EP1716173B8 (de) 2004-02-11 2012-06-27 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
CN101616693A (zh) 2006-11-24 2009-12-30 泰根尼克斯股份有限公司 用于鉴定软骨细胞表型稳定性以及筛选软骨形成影响因子的标记基因
EP3184548A1 (de) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimärer antigenrezeptor mit zytokinrezeptoraktivierender oder -blockierender domäne

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010419A2 (en) * 1994-10-03 1996-04-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
DE19516673A1 (de) * 1995-04-28 1996-10-31 Gabriele Dr Pecher Vakzine gegen Tumorerkrankungen
DE19617837A1 (de) * 1996-04-19 1997-10-23 Gabriele Dr Pecher Dendritische Zellen transfiziert mit Muzin-cDNA als Vakzine gegen humane Tumorerkrankungen
WO1997040182A1 (de) * 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
WO2000034494A1 (en) * 1998-12-09 2000-06-15 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010419A2 (en) * 1994-10-03 1996-04-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
DE19516673A1 (de) * 1995-04-28 1996-10-31 Gabriele Dr Pecher Vakzine gegen Tumorerkrankungen
DE19617837A1 (de) * 1996-04-19 1997-10-23 Gabriele Dr Pecher Dendritische Zellen transfiziert mit Muzin-cDNA als Vakzine gegen humane Tumorerkrankungen
WO1997040182A1 (de) * 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
WO2000034494A1 (en) * 1998-12-09 2000-06-15 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACRES R B ET AL: "VACCINIA VIRUS MUC1 IMMUNIZATION OF MICE: IMMUNE RESPONSE AND PROTECTION AGAINST THE GROWTH OF MURINE TUMORS BEARING THE MUC1 ANTIGEN", JOURNAL OF IMMUNOTHERAPY,US,RAVEN PRESS, NEW YORK, vol. 14, 1993, pages 136 - 143, XP000764845, ISSN: 1053-8550 *
BALLOUL J - M ET AL: "RECOMBINANT MUC 1 VASSINIA VIRUS: A POTENTIAL VECTOR FOR IIMUNITHERAPY OF BREAST CANCER", CELLULAR AND MOLECULAR BIOLOGY,CMB ASSOCIATIONS, NOISY-LE-GRAND,FR, vol. 40, no. 1, 1994, pages 49 - 59, XP000561067, ISSN: 0145-5680 *
BIZOUARNE N ET AL: "Immunotherapy of breast cancer using a recombinant Vaccinia virus expressing the human MUC1 and IL2 genes", BREAST CANCER. ADVANCES IN BIOLOGY AND THERAPEUTICS,XX,XX, no. 21, 1996, pages 303 - 308, XP002075465 *
GRAHAM R A ET AL: "The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine", CANCER IMMUNOLOGY AND IMMUNOTHERAPY,DE,BERLIN, vol. 2, no. 42, 1996, pages 71 - 80, XP002075466, ISSN: 0340-7004 *
KANTOR J ET AL: "ANTITUMOR ACTIVITY AND IMMUNE RESPONSES INDUCED BY A RECOMBINANT CARCINOEMBRYONIC ANTIGEN-VACCINIA VIRUS VACCINE", JOURNAL OF THE NATIONAL CANCER INSTITUTE,US,US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, vol. 84, no. 14, 15 July 1992 (1992-07-15), pages 1084 - 1091, XP000566534, ISSN: 0027-8874 *

Also Published As

Publication number Publication date
WO2001024832A2 (de) 2001-04-12
EP1409534A2 (de) 2004-04-21
DE10048710A1 (de) 2001-10-04
AU1991901A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AU6787894A (en) Adenoviral vectors of animal origin and use in gene therapy
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1998049300A3 (en) Truncated vegf-related proteins
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
NZ289899A (en) Peptide which binds to the p53 suppressor site of the MDM2 oncogene
HUP9901254A2 (hu) Nemdendrites szerkezetű gerincet alkotó peptid hordozó
WO1999054461A3 (de) Menschliche nukleinsäuresequenzen aus endometriumtumorgewebe
WO1999047669A3 (de) Menschliche nukleinsäuresequenzen aus brusttumorgewebe
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
CA2349506A1 (en) A method for selective expression of therapeutic genes by hyperthermia
AU2633497A (en) Peptides having antiproliferative properties
WO1998059040A3 (de) Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
EP1169441B8 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
DE69732029D1 (de) Dna enthaltende impfstoffen
EP1536006A4 (de) Krebsantigene und deren nutzung
AU8243198A (en) Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors
WO2001024832A3 (de) Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
WO2001019852A8 (en) Methods of peptide preparation
GB0031430D0 (en) Polypeptides
WO2003031569A3 (en) Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
WO2001003728A3 (en) Gene therapy for enhancing and/or inducing angiogenesis
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000982945

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000982945

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000982945

Country of ref document: EP